The Startup MDVisit Website →
← Back to blog

Audit Ready FDA Software Validation: CSA Checklist for U.S. Healthtech

September 7, 2026
Audit Ready FDA Software Validation: CSA Checklist for U.S. Healthtech

FDA requires validated software for any system used in device production, design, or the quality management system, under 21 CFR Part 820. The agency's two anchor documents are the General Principles of Software Validation and the Computer Software Assurance guidance. "Done" means you can produce a documented SRS, a risk assessment, a traceability matrix, and stored validation evidence on demand.

TL;DR:

  • Validation efforts should prioritize high-risk functions like medication dosing with in-depth testing and comprehensive documentation.
  • Risk-based assurance allows for less scripted testing on low-risk features, provided the rationale and evidence are properly documented.
  • Traceability matrices linking requirements, tests, and evidence must be established early and maintained throughout development to withstand reviews.
  • Using third-party cloud platforms does not eliminate validation responsibilities, though vendor evidence can support and reduce testing burdens.
  • Most validation failures stem from unclear intended use, weak requirements, and traceability gaps, especially for high-risk functions.

Table of Contents

Which FDA Guidances Govern Software Validation?

Two documents define your obligations, and they work together rather than as substitutes.

The General Principles of Software Validation is the foundational text. It covers software that is itself a medical device, software embedded in a device, and software used to design, develop, or manufacture devices. It describes lifecycle planning, verification, and validation activities in detail.

The Computer Software Assurance guidance narrows in on one category: software used in production and the quality management system. It supplements, and for that category largely supersedes, the older Section 6 approach with a risk-based assurance model that permits less scripted testing where risk is low.

Your compliance map should include:

  • 21 CFR §820.30(g) for design validation of the device itself
  • 21 CFR §820.70(i) for software used in production or the QMS
  • ISO 13485 alignment, since FDA's Quality System Regulation was harmonized toward this international standard

What Do Verification, Validation, and Risk-Based Assurance Actually Mean?

Verification asks whether you built the software right. Validation asks whether you built the right software for its intended use. A unit test confirming a function returns the correct dosage calculation is verification. Confirming that clinicians actually use that calculation correctly in a live workflow is validation.

Risk-based assurance is the mechanism that scales your effort to match the stakes. A feature that determines medication dosing warrants deep scripted testing and multiple reviewers. A cosmetic UI change on an internal reporting dashboard does not need the same rigor, and treating it as if it does wastes resources you need elsewhere.

  • Define intended use before writing a single test case
  • Rank each function by patient or process risk
  • Match evidence depth to that ranking, not to habit

Pro Tip: Auditors rarely fault a lean validation record if the risk rationale is documented. They fault records where the rationale is missing and the depth looks arbitrary.

A "validated state" is not a one-time achievement. FDA expects ongoing monitoring, defined triggers for revalidation, and controls that catch drift before it becomes a defect.

What Documentation Does FDA Expect Across the Software Lifecycle?

Your Design History File or QMS records need a clear paper trail connecting requirements to evidence. Reviewers should be able to follow that trail without asking you to fill gaps from memory.

  1. Software Requirements Specification (SRS) describing intended use and functional requirements tied to clinical or operational scenarios
  2. Design outputs showing how requirements translate into architecture and code-level decisions
  3. Verification records documenting unit, integration, and system-level test results
  4. Traceability matrix linking each requirement to its test case and resulting evidence
  5. Configuration management logs tracking versions, builds, and environment settings
  6. Change control records capturing what changed, why, and what was retested

Traceability is where most files fall apart under review. Every high-risk requirement needs at least one objective acceptance criterion and a linked test result, plus supporting artifacts like a test log or sign-off note. Version every document, require named review signatures, and store supplier evidence alongside your own records rather than in a separate system nobody checks during an inspection. Teams building this structure early tend to reference our clinical product development framework to keep verification and validation activities distinct from the start.

Is CSA Replacing CSV, and What Testing Methods Qualify Now?

Traditional Computer System Validation (CSV) leans on exhaustive scripted test scripts for nearly everything, regardless of risk. Computer Software Assurance flips that logic: it asks what evidence is actually needed to establish confidence that software is fit for its intended use, then lets teams apply the least burdensome method that gets there.

Activities FDA accepts under a documented CSA rationale include:

  • Exploratory or unscripted testing for lower-risk features
  • Continuous performance monitoring in place of repeated regression scripts
  • Ongoing data monitoring that flags anomalies as they occur
  • Supplier-provided test evidence, when the supplier relationship supports it

Unscripted testing is not a free pass to skip documentation. You still need a written rationale explaining why the approach fits the risk level, the scope of what was tested, and a results summary an outside reviewer could follow. Experts describe this shift as a move away from testing everything identically, focused instead on the functions that actually touch patient safety or product quality.

How Should You Build a Validation Program This Quarter?

A defensible validation program follows a sequence. Skipping steps to save time almost always costs more time later, when an auditor asks for evidence that does not exist.

  1. Define intended use and scope. Write or update the SRS against real clinical or operational use cases, not abstract feature lists. Our guide on developing a clinical use case walks through this step for SaaS teams specifically.
  2. Run a software risk assessment. Rank every function by its potential impact on patient safety or process integrity.
  3. Write the validation plan. Set acceptance criteria, assign responsibilities, set timelines, and specify exactly what evidence each activity must produce.
  4. Choose your verification and testing strategy. Match the method (unit, integration, system, or user-site testing) to the assurance level the risk assessment assigned, and document the rationale for any exploratory testing.
  5. Assemble the traceability matrix. Package it with supporting evidence into the DHF or QMS, then route it through formal review and sign-off.
  6. Set monitoring and revalidation triggers. Define what change, defect rate, or performance shift automatically kicks off a revalidation cycle.

Pro Tip: Build your traceability matrix in step one, not step five. Retrofitting traceability after testing is finished is where most teams lose weeks they didn't budget for.

Monitoring obligations don't end at launch. Our post-market surveillance guide covers how to structure that ongoing performance tracking so revalidation triggers are caught early rather than discovered during an inspection.

Who Is Responsible When Software Runs on a Cloud or SaaS Platform?

Using a third-party cloud platform does not transfer your validation obligation. FDA holds the manufacturer responsible for validating intended use regardless of who wrote the underlying code or where it runs.

Supplier evidence can reduce, but never eliminate, your own testing burden:

  • Developer test summaries and vendor validation reports
  • Security attestations such as SOC 2, particularly relevant given medical device cybersecurity expectations
  • Change logs and service level agreements showing how the vendor manages updates
  • Documentation supporting 21 CFR Part 11 controls where electronic records and signatures are involved

The cloud delivery model matters here. An IaaS arrangement leaves most validation work on your side, while a mature SaaS vendor with strong change control documentation can shift real weight off your team, provided you keep that evidence on file and reference it in your own risk rationale.

What Are the Most Common Software Validation Mistakes?

Most validation failures trace back to a handful of recurring errors, and they show up in inspection findings often enough to be predictable.

  • Ambiguous or missing statement of intended use
  • A weak SRS that leaves testers guessing what "correct" means
  • Over-testing low-risk features while under-documenting high-risk ones
  • Traceability gaps between requirements and test evidence
  • No revalidation trigger tied to change control, so updates ship untested

FDA's own analysis, cited in its foundational software validation guidance, found that software defects have historically been a significant contributor to device recalls, which is precisely why validation and change control sit at the center of the regulation rather than at the edges.

A working defensibility checklist covers: documented intended use, a reviewed SRS, a completed risk assessment, a linked traceability matrix, testing matched to risk level, stored and versioned evidence, formal change control, and a defined monitoring cadence. Practitioners consistently point to unclear intended use and thin SRS documents as the root cause behind most validation gaps, and closing those two items first tends to resolve a disproportionate share of downstream problems.

Why Startups Need a Leaner, Risk-Prioritized Validation Approach

Healthcare SaaS founders rarely have the headcount to run exhaustive scripted validation across every feature, and they don't need to. A lean, risk-prioritized program that produces traceable, reviewable evidence typically holds up better under audit than a bloated one built on templates copied from a much larger organization.

Paul Bergeron, MD, MBA, brings that lens to healthcare SaaS advisory work. A typical engagement walks a founding team through defining intended use, drafting the SRS, facilitating the risk assessment, and assembling evidence into an audit-ready structure before an inspector or investor ever asks for it. The goal is a validation posture proportionate to the company's actual risk profile, not a mirror of enterprise process built for a team ten times the size.

— Paul Bergeron MD, MBA

Need Help Turning FDA Guidance Into an Audit-Ready Program?

Reading the guidance is one thing. Turning it into a working SRS, a defensible risk assessment, and a traceability matrix that survives inspection is a different job, and it's the job most healthcare SaaS teams underestimate until they're mid-fundraise or mid-audit. The StartupMD works with healthcare SaaS founders and executives as a fractional Chief Medical Officer and regulatory advisory partner, translating the CSA framework into a validation program sized correctly for a startup's stage and risk profile.

The StartupMD

An engagement typically starts with a scoped review of your current validation posture: where your SRS is thin, where risk ranking is missing, and where traceability would collapse under a real inspection. From there, the work centers on closing those gaps with documentation your team can actually maintain going forward, not a one-time binder that goes stale after the next release. If your team is preparing for a submission, an audit, or a diligence review, explore the Startup Clinical Advisory Scope to see how a fractional advisory engagement is structured, or visit The StartupMD's services page to start a conversation about your specific validation gaps.

Sources